James is the Vice President of Bioprocessing & Applications at MicrofluidX, where they are developing the Cyto Engine, a cell therapy bioprocessing and manufacturing platform.
James has experience in cell and gene therapy process development and manufacturing optimisation. His work has focused on understanding the translational requirements for robust product realisation, considering aspects such as process development, manufacturability and ultimately the clinical adoption and health economic implications. His technical experience has been focused on GMP protocol adaptation and the translational work required for GMP manufacturing of cell and gene therapies. Additionally, James has a background in Medicinal Chemistry, International Business and Health economics
Also Speaking
Jeffrey Boyd
Partner, Global Healthcare & Life Sciences Practice • Heidrick & Struggles
19 November 2022
Also Speaking
Investor List
Take a look at some of the investors who attended Advanced Therapies Week 2023.
6 January 2023